SIC
TGTX icon

SJS Investment Consulting’s TG Therapeutics TGTX Stock Holding History

SJS Investment Consulting’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.37K Buy
116
+100
+625% +$4.09K ﹤0.01% 1280
2026
Q1 		$532 Buy
16
+4
+33% +$119 ﹤0.01% 1716
2025
Q4 		$358 Buy
12
+6
+100% +$196 ﹤0.01% 1633
2025
Q3 		$217 Hold
6
– – ﹤0.01% 1444
2025
Q2 		$216 Sell
6
-5
-45% -$186 ﹤0.01% 1358
2025
Q1 		$434 Hold
11
– – ﹤0.01% 1295
2024
Q4 		$332 Buy
+11
New +$316 ﹤0.01% 1371

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SJS Investment Consulting's TGTX Position: Q2 2026 in Review

SJS Investment Consulting increased its TG Therapeutics (TGTX) stake by 625% in Q2 2026, buying an estimated $4.09K and bringing the position to 116 shares worth $6.37K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.

SJS Investment Consulting first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • SJS Investment Consulting held 116 shares of TG Therapeutics worth $6.37K as of Q2 2026.
  • SJS Investment Consulting bought 100 TG Therapeutics shares in Q2 2026, an estimated $4.09K.
  • TG Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1280 holding.
  • SJS Investment Consulting first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.